In 2022, Hisamitsu Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hisamitsu Pharmaceutical has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
Total Scope 1 | 7,862a | 6,923a | 6,986a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 14,278a | 15,862a | 14,919a | |
Total Scope 3 | 98,488a | 93,816a | 89,353a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 7.5606a | 6.4314a | 5.4335a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2022, the total operational greenhouse gas (GHG) emissions of Hisamitsu Pharmaceutical amounted to 22,140 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2021, the total operational greenhouse gas (GHG) emissions of Hisamitsu Pharmaceutical decreased by 2.83%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2022, the total Scope 1 emissions of Hisamitsu Pharmaceutical were 7,862 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Hisamitsu Pharmaceutical's Scope 1 emissions have decreased by 10.27%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2021), Hisamitsu Pharmaceutical's Scope 1 emissions increased by 13.56%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2022, Hisamitsu Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 14,278 tCO₂e without specifying the calculation method.a
Since 2019, Hisamitsu Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Hisamitsu Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2021), Hisamitsu Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Hisamitsu Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2022, Hisamitsu Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2022, Hisamitsu Pharmaceutical reported 98,488 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2022 disclosure of Hisamitsu Pharmaceutical includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2021, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2022, Hisamitsu Pharmaceutical reported total Scope 3 emissions of 98,488 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 72.77% of these emissions originated from upstream activities such as purchased goods and capital goods, while 27.23% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Hisamitsu Pharmaceutical's Scope 3 emissionshave remained relatively stable, indicating that Hisamitsu Pharmaceutical's emissions have plateaued with no significant change in its value chain footprint.a
Compared to the previous year (2021), Hisamitsu Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Hisamitsu Pharmaceutical's emissions have plateaued with no significant change in its value chain footprint.a
In 2022, Hisamitsu Pharmaceutical reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2022, the largest contributors to Hisamitsu Pharmaceutical's Scope 3 emissions were:a
In 2022, Hisamitsu Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 7,862 tCO₂e and total revenues of USD 1,040 millions. This translates into an emissions intensity of 7.56 tCO₂e per millions USD.a
In 2022, Hisamitsu Pharmaceutical reported a Scope 1 emissions intensity of 7.56 tCO₂e per millions USD. Compared to the peer group median of 12.01, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2022, Hisamitsu Pharmaceutical ranked 8 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Hisamitsu Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2022, Hisamitsu Pharmaceutical reported a total carbon footprint of 120,628 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 3.45% increase compared to 2021, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Hisamitsu Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 81.65% of the company's total carbon footprint, followed by Scope 2 emissions at 11.84%.a